Data on Chimerix's Brincidofovir Suggests Favorable

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Data on Chimerix's Brincidofovir Suggests Favorable Resistance Profile in Adenovirus and Cytomegalovirus (CMV)

-- First-Line Use of Brincidofovir for CMV May Preserve Subsequent Therapeutic Options --

-- Data Presented at 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) --

DURHAM, N.C., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX ), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced new data today that suggests a potentially favorable resistance profile for brincidofovir for the treatment of life-threatening adenovirus and the prevention and treatment of cytomegalovirus (CMV). Results of the in vitro (cell culture) and Phase 2 studies were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.

"Drug resistance can be a significant issue in the treatment of viral diseases, particularly in immunocompromised patients," said M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix. "We are encouraged by the high barrier to resistance seen in early studies for brincidofovir in adenovirus and we look forward to gathering more data through our Phase 3 AdVise study, which is currently enrolling patients. Additionally, the data for CMV suggest that first-line use of brincidofovir preserves the option for subsequent therapies, clearly a desirable feature in any first-line CMV prevention."

Resistance Profile of Adenovirus Exposed to Brincidofovir In Vitro and In Vivo (Abstract V-1302)

In an in vitro study of human adenovirus, brincidofovir and cidofovir were evaluated in increasing concentrations for antiviral activity. The development of brincidofovir-resistant adenovirus required two mutations to decrease brincidofovir's activity by four-to-eight-fold. These mutations required more than five months of exposure to brincidofovir in cell culture before they emerged.

In an exploratory Phase 2 study, 48 allogeneic hematopoietic cell transplant recipients with asymptomatic adenovirus levels ≥ 100 c/mL were randomized to placebo, brincidofovir once weekly, or brincidofovir twice weekly for 12 weeks. At 12 weeks, only one subject was identified with adenovirus containing one of the mutations detected in vitro . The mutation observed may have been present prior to brincidofovir therapy since previous use of antivirals, including cidofovir, was not excluded.

These data provide preliminary evidence that brincidofovir resistance to adenovirus may be slow to emerge in humans.

Combination Activity and Emerging Resistance Profile of Brincidofovir in CMV Prevention and Treatment (Abstract V-677)

The combination activity and resistance profile of brincidofovir for CMV were evaluated in vitro and in two Phase 2 clinical trials. Study 201 enrolled 171 antiviral-naïve patients with CMV and Study 350 enrolled 210 heavily pre-treated patients with life-threatening DNA viral infections, including 107 patients with CMV as the primary viral infection.

In vitro , brincidofovir selected a unique mutation in the CMV DNA polymerase that led to slower virus replication and resistance to brincidofovir or cidofovir, but not cross-resistance to ganciclovir or foscarnet.

In Study 201, no resistance-associated mutations were detected, suggesting first-line use of brincidofovir may not cause cross-resistance. In Study 350, 59 patients were evaluable and had baseline sequence data available. Two evaluable patients had baseline CMV DNA polymerase mutations associated with resistance to ganciclovir, cidofovir, or brincidofovir. These two patients did not achieve viral levels below measurable quantity (less than 200 virus copies per mL in plasma) at the last time on therapy. However, of the remaining evaluable patients with baseline sequence available, including many who were resistant to ganciclovir with common mutations, 25 (44%) achieved viral levels below 200 copies per mL and 36 (63%) had at least a 0.5 log10 decrease in viral load.

The results suggest that while the prior use of CMV antivirals leading to resistance-associated mutations can reduce brincidofovir activity, first-line use of brincidofovir for CMV prevention may preserve subsequent therapeutic options.

About Brincidofovir (CMX001)

Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown broad-spectrum in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenovirus. Brincidofovir has shown no evidence of kidney or bone marrow toxicity in nearly 900 patients treated to date. Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial. Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.

About Adenovirus

Adenovirus causes upper respiratory infections, including the common cold, in individuals with intact immune systems; however, it is often rapidly fatal in patients with compromised immune responses. Adenovirus is most common during the post-transplant period when the immune system is weak. No therapies are approved for the treatment of adenovirus.

About Cytomegalovirus (CMV)

CMV is a member of the herpes virus family and remains the most common cause of fatal infections in hematopoietic cell transplant (HCT) recipients. Two-thirds of adults have been exposed to CMV, generally in childhood, with lifelong viral latency established following the initial infection. In immunocompromised individuals, such as transplant recipients, CMV often reactivates during the post-transplant period when the immune system is weak. CMV itself is immunosuppressive and reactivation of the virus can predispose a person to other opportunistic infections. No therapies are approved for the prevention of CMV in HCT recipients.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant (HCT) recipients. In addition, Chimerix is enrolling the pilot portion of the Phase 3 AdVise trial of brincidofovir for treatment of adenovirus (AdV) infection. Chimerix is also working with BARDA to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com .

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications 919-287-4125

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 58

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 42

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 174

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 15

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 203

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 22

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 15

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 282

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 113

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

BIEL Crystal's Innovative Smartphone Glass Cover Revolutionizes Durability

Updated Category News Views 299

BIEL Crystal's Innovative Smartphone Glass Cover BIEL Crystal, a notable supplier for Apple and a leader in smart device components, has recently introduced its cutting-edge product, the "Witch Cloak." This ultra-hard coating smartphone glass cover represents a significant advancement in the technology used to protect smartphones from daily wear and tear, notably featured...

Continue Reading
Covenant Clearinghouse Triumphs in Legal Battle with Chicago Title

Updated Category News Views 780

Covenant Clearinghouse Triumphs in Legal Battle Covenant Clearinghouse recently achieved a significant legal victory against the Chicago Title Company, concluding a complex litigation case. The case, documented as Chicago Title Ins. Co. v. Covenant Clearinghouse, LLC, revolved around crucial property rights under the Illinois Transfer Fee Covenant Act. Legal Proceedings...

Continue Reading
TTEC CEO's Buyout Proposal: What It Means for Stakeholders

Updated Category News Views 137

TTEC's CEO Buyout Proposal: Evaluating the Future TTEC Holdings, Inc. (NASDAQ: TTEC), known for its AI-driven customer experience solutions, is currently assessing a buyout proposal presented by its CEO, Kenneth Tuchman. This significant move has prompted the company to engage the services of Rothschild & Co as its financial advisor, alongside legal support from Skadden,...

Continue Reading
Primech AI Unveils HYTRON LITE Bathroom Cleaning Solution

Updated Category News Views 167

Primech AI Launches Innovative HYTRON LITE at Industry Event Primech AI Pte. Ltd. (Nasdaq: PMEC) is making waves in the robotics industry with its latest innovative creation, the HYTRON LITE bathroom cleaning robot, introduced during a significant event focused on facilities management. This gathering, that united key players, took place at Temasek Polytechnic and was...

Continue Reading
The Growth Journey of Travelers Companies: A Five-Year Analysis

Updated Category News Views 255

Understanding Travelers Companies' Market Performance When evaluating the potential return on investment in stocks, it's essential to look at the historical performance of companies like Travelers Companies (NYSE: TRV). This prominent insurance provider has shown remarkable consistency and growth over the years, recently achieving a market capitalization of $63.96...

Continue Reading